145 related articles for article (PubMed ID: 1694851)
41. The involvement of proteoglycans in the human plasma prekallikrein interaction with the cell surface.
Veronez CL; Nascimento FD; Melo KR; Nader HB; Tersariol IL; Motta G
PLoS One; 2014; 9(3):e91280. PubMed ID: 24621563
[TBL] [Abstract][Full Text] [Related]
42. Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor.
Scott CF; Silver LD; Schapira M; Colman RW
J Clin Invest; 1984 Apr; 73(4):954-62. PubMed ID: 6561202
[TBL] [Abstract][Full Text] [Related]
43. Kinin release from high molecular weight kininogen by the action of Hageman factor in the absence of kallikrein.
Wiggins RC
J Biol Chem; 1983 Jul; 258(14):8963-70. PubMed ID: 6553057
[TBL] [Abstract][Full Text] [Related]
44. Immunologic studies of human coagulation factor XI and its complex with high molecular weight kininogen.
Bouma BN; Vlooswijk RA; Griffin JH
Blood; 1983 Nov; 62(5):1123-31. PubMed ID: 6626744
[TBL] [Abstract][Full Text] [Related]
45. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen.
Revak SD; Cochrane CG; Griffin JH
J Clin Invest; 1977 Jun; 59(6):1167-75. PubMed ID: 864009
[TBL] [Abstract][Full Text] [Related]
46. The role of prekallikrein and high-molecular-weight kininogen in the contact activation of Hageman factor (factor XII) by sulfatides and other agents.
España F; Ratnoff OD
J Lab Clin Med; 1983 Oct; 102(4):487-99. PubMed ID: 6604770
[TBL] [Abstract][Full Text] [Related]
47. Activation of the contact system of coagulation by a monoclonal antibody directed against a neodeterminant in the heavy chain region of human coagulation factor XII (Hageman factor).
Nuijens JH; Huijbregts CC; Eerenberg-Belmer AJ; Meijers JC; Bouma BN; Hack CE
J Biol Chem; 1989 Aug; 264(22):12941-9. PubMed ID: 2473984
[TBL] [Abstract][Full Text] [Related]
48. The role of bovine high-molecular-weight (HMW) kininogen in contact-mediated activation of bovine factor XII: interaction of HMW kininogen with kaolin and plasma prekallikrein.
Ikari N; Sugo T; Fujii S; Kato H; Iwanaga S
J Biochem; 1981 Jun; 89(6):1699-709. PubMed ID: 6912861
[TBL] [Abstract][Full Text] [Related]
49. Conformational analysis of synthetic peptides encompassing the factor XI and prekallikrein overlapping binding domains of high molecular weight kininogen.
You JL; Page JD; Scarsdale JN; Colman RW; Harris RB
Peptides; 1993; 14(5):867-76. PubMed ID: 8284263
[TBL] [Abstract][Full Text] [Related]
50. Calorimetric and spectroscopic examination of the solution phase structures of prekallikrein binding domain peptides of high molecular weight kininogen.
You JL; Scarsdale JN; Harris RB
J Protein Chem; 1991 Jun; 10(3):301-11. PubMed ID: 1910462
[TBL] [Abstract][Full Text] [Related]
51. Role of arginine residues in the coagulant activity of high molecular weight kininogen.
Chang JJ; Scott CF; Colman RW
Blood; 1986 Mar; 67(3):805-10. PubMed ID: 3633200
[TBL] [Abstract][Full Text] [Related]
52. Hageman factor-dependent pathways: mechanism of initiation and bradykinin formation.
Kaplan AP
Fed Proc; 1983 Nov; 42(14):3123-7. PubMed ID: 6556144
[TBL] [Abstract][Full Text] [Related]
53. Interactions among Hageman factor (HG, Factor XII), plasma thromboplastin antecedent (PTA, Factor XI), plasma prekallikrein (PK, Fletcher factor) and high molecular weight kininogen (HMW-K, Fitzgerald factor) in blood coagulation.
Saito H; Ratnoff OD
Adv Exp Med Biol; 1979; 120B():61-70. PubMed ID: 517254
[TBL] [Abstract][Full Text] [Related]
54. Protein-protein interactions in contact activation of blood coagulation. Characterization of fluorescein-labeled human high molecular weight kininogen-light chain as a probe.
Bock PE; Shore JD
J Biol Chem; 1983 Dec; 258(24):15079-86. PubMed ID: 6558074
[TBL] [Abstract][Full Text] [Related]
55. Molecular assembly in the contact phase of the Hageman factor system.
Cochrane CG; Griffin JH
Am J Med; 1979 Oct; 67(4):657-64. PubMed ID: 386794
[TBL] [Abstract][Full Text] [Related]
56. Identification of an endothelial cell binding site on kininogen domain D3.
Herwald H; Hasan AA; Godovac-Zimmermann J; Schmaier AH; Müller-Esterl W
J Biol Chem; 1995 Jun; 270(24):14634-42. PubMed ID: 7540175
[TBL] [Abstract][Full Text] [Related]
57. Abnormalities in the contact activation through factor XII in Fujiwara trait: a deficiency in both high and low molecular weight kininogens with low level of prekallikrein.
Oh-ishi S; Ueno A; Uchida Y; Katori M; Hayashi H; Koya H; Kitajima K; Kimura I
Tohoku J Exp Med; 1981 Jan; 133(1):67-80. PubMed ID: 6785899
[TBL] [Abstract][Full Text] [Related]
58. Association of factor XI and high molecular weight kininogen in human plasma.
Thompson RE; Mandle R; Kaplan AP
J Clin Invest; 1977 Dec; 60(6):1376-80. PubMed ID: 915004
[TBL] [Abstract][Full Text] [Related]
59. Prekallikrein deficiency in a kindred with kininogen deficiency and Fitzgerald trait clotting defect. Evidence that high molecular weight kininogen and prekallikrein exist as a complex in normal human plasma.
Donaldson VH; Kleniewski J; Saito H; Sayed JK
J Clin Invest; 1977 Sep; 60(3):571-83. PubMed ID: 893663
[TBL] [Abstract][Full Text] [Related]
60. High molecular weight kininogen potentiates the heparin-accelerated inhibition of plasma kallikrein by antithrombin: role for antithrombin in the regulation of kallikrein.
Olson ST; Sheffer R; Francis AM
Biochemistry; 1993 Nov; 32(45):12136-47. PubMed ID: 7692967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
